Ranked #2,849 of 8,699 institutional investors
Silverarc Capital Management, LLC
Boston, MA
$747M
US stock portfolio at live prices · today −$2.2M (−0.29%)
Market closed. Prices as of Nov 20, 8:41 AM ET
- Value at quarter end (Q3 2026)
- $821M
- Change from Q2 2026
- −$77.6M (−8.63%)
- Positions
- 51 · 11 new, 13 sold out
- Filed
- Nov 12, 2026
Not counted in the ranking: call options on $30.8M of stock, put options on $2.7M. $139M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesKOD 9.83%CELC 6.05%COGT 5.84%RYTM 5.44%SGMT 4.82%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| KOD Kodiak Sciences Inc. | 750,170 | $73.4M | 9.83% | Added +37% |
| CELC Celcuity Inc. | 803,193 | $45.2M | 6.05% | Added +60% |
| COGT Cogent Biosciences, Inc. | 1,574,698 | $43.7M | 5.84% | Added +23% |
| RYTM Rhythm Pharmaceuticals, Inc. | 348,317 | $40.7M | 5.44% | Added +12% |
| SGMT Sagimet Biosciences Inc. | 3,745,990 | $36.0M | 4.82% | Added +28% |
| IMNM Immunome, Inc. | 2,092,715 | $34.8M | 4.65% | Added +4% |
| BIIB Biogen Inc. | 112,790 | $27.9M | 3.73% | Added +134% |
| GLUE Monte Rosa Therapeutics, Inc. | 3,112,773 | $27.7M | 3.71% | Added +181% |
| ORKA Oruka Therapeutics, Inc. | 247,918 | $24.2M | 3.24% | Reduced −30% |
| IMVT Immunovant, Inc. | 624,055 | $20.3M | 2.72% | Added +1% |
| DNTH Dianthus Therapeutics, Inc. | 236,582 | $20.1M | 2.69% | Reduced −39% |
| ERAS Erasca, Inc. | 1,330,455 | $18.9M | 2.53% | Added +5% |
| SYRE Spyre Therapeutics, Inc. | 151,151 | $14.8M | 1.97% | Added +152% |
| ABVX ABIVAX Société Anonyme | 175,699 | $14.2M | 1.90% | Added +4% |
| OVID Ovid Therapeutics Inc. | 5,950,000 | $13.9M | 1.86% | Added +92% |
| CLDX Celldex Therapeutics, Inc. | 487,589 | $13.6M | 1.82% | New |
| AVLN Avalyn Pharma Inc. | 378,352 | $10.9M | 1.45% | Added +14% |
| DFTX Definium Therapeutics, Inc. | 345,946 | $10.2M | 1.36% | Reduced −14% |
| CCCC C4 Therapeutics, Inc. | 3,454,647 | $8.4M | 1.13% | Added +14% |
| ZBIO Zenas BioPharma, Inc. | 334,057 | $8.4M | 1.12% | Reduced −34% |
| SVRA Savara Inc. | 1,518,833 | $7.9M | 1.06% | Added +12% |
| CERS Cerus Corporation | 3,950,595 | $7.5M | 1.00% | Added +14% |
| PCVX Vaxcyte, Inc. | 125,080 | $7.3M | 0.98% | Reduced −14% |
| ALXO ALX Oncology Holdings Inc. | 6,565,960 | $6.7M | 0.90% | Added +14% |
| CMPS COMPASS Pathways plc | 717,356 | $6.2M | 0.83% | Added +43% |
| PRAX Praxis Precision Medicines, Inc. | 19,753 | $6.1M | 0.82% | Reduced −70% |
| ELVN Enliven Therapeutics, Inc. | 121,452 | $5.6M | 0.75% | Reduced −75% |
| SLDB Solid Biosciences Inc. | 760,337 | $4.9M | 0.66% | Added +14% |
| EVMN Evommune Inc | 594,027 | $4.3M | 0.58% | New |
| YARW Yarrow Bioscience, Inc. | 301,919 | $4.3M | 0.57% | New |
| IBIO iBio, Inc. | 5,357,088 | $4.3M | 0.57% | Added +52% |
| BNTC Benitec Biopharma Inc. | 443,109 | $3.6M | 0.48% | Reduced −35% |
| IRON Disc Medicine, Inc. | 47,312 | $3.6M | 0.48% | Reduced −43% |
| ARCT Arcturus Therapeutics Holdings Inc. | 459,899 | $3.5M | 0.47% | New |
| BLSM BlossomHill Therapeutics, Inc. | 202,104 | $2.9M | 0.39% | New |
| SNDX Syndax Pharmaceuticals, Inc. | 247,418 | $2.3M | 0.30% | Reduced −80% |
| PALI Palisade Bio, Inc. | 2,335,602 | $2.2M | 0.29% | New |
| MRNA Moderna, Inc. | 10,000 | $2.0M | 0.27% | New |
| ANL Adlai Nortye Group Ltd. | 216,617 | $2.0M | 0.26% | New |
| ZVRA Zevra Therapeutics, Inc. | 200,260 | $1.8M | 0.24% | New |
| ELUT Elutia Inc. | 2,192,980 | $1.8M | 0.24% | Unchanged |
| ABEO Abeona Therapeutics Inc. | 693,441 | $1.7M | 0.23% | Added +14% |
| TELA TELA Bio, Inc. | 2,137,201 | $1.6M | 0.21% | Unchanged |
| CTNM Contineum Therapeutics, Inc. | 158,964 | $1.4M | 0.19% | Reduced −46% |
| ORIC ORIC Pharmaceuticals, Inc. | 160,552 | $1.2M | 0.17% | Reduced −78% |
| FTH Faeth Therapeutics, Inc. | 124,098 | $1.1M | 0.14% | New |
| QUIT Achieve Life Sciences, Inc. | 158,950 | $933K | 0.12% | Reduced −30% |
| RAPP Rapport Therapeutics, Inc. | 35,524 | $838K | 0.11% | New |
| ACRS Aclaris Therapeutics, Inc. | 238,541 | $835K | 0.11% | Reduced −88% |
| CAMP Camp4 Therapeutics Corp | 183,063 | $732K | <0.1% | Reduced −72% |
| CLRB Cellectar Biosciences, Inc. | 151,118 | $133K | <0.1% | Reduced −53% |
Sold out in Q3 2026
| Stock | Shares held at Q2 2026 | Worth today |
|---|---|---|
| GH Guardant Health, Inc. | 99,826 | $14.5M |
| MANE Veradermics Inc | 95,000 | $11.8M |
| TRVI Trevi Therapeutics, Inc. | 678,095 | $9.3M |
| VCYT Veracyte, Inc. | 318,001 | $8.0M |
| XENE Xenon Pharmaceuticals Inc. | 186,821 | $7.0M |
| WGS GeneDx Holdings Corp. | 122,269 | $6.0M |
| INSM Insmed Incorporated | 34,438 | $5.0M |
| AVTX Avalo Therapeutics, Inc. | 500,402 | $3.4M |
| ARTV Artiva Biotherapeutics, Inc. | 525,000 | $2.0M |
| RVMD Revolution Medicines, Inc. | 10,000 | $1.6M |
| SION Sionna Therapeutics, Inc. | 42,478 | $126K |
| FHTX Foghorn Therapeutics Inc. | 45,975 | $82K |
| KPTIQ Karyopharm Therapeutics Inc. | 297,460 | $10K |